Hepatitis B virus reactivation andalemtuzumab therapy

Vincenzo Abbadessa, Antonio Craxi, Rosa Di Stefano, Donatella Ferraro, Antonino Mule', Emanuele Ammatuna, Giuseppina Calvaruso

Risultato della ricerca: Article

99 Citazioni (Scopus)

Abstract

Reactivation of hepatitis B virus infection in subjects receiving cytotoxic treatment for heamatological malignancies occurs in 21–53% of chronic HBsAg carriers and in an unknown number of HBsAg negative subjects harbouring occult HBV infection. Immmunotherapy with alemtuzumab, a humanized monoclonal antibody against CD52 epitopes on lymphocytes cells produces deep immunosuppression. We describe two subjects with chronic lymphocytic leukaemia and occultHBV infection who developed a virological and biochemical flare of hepatitis B following immunotherapy with alemtuzumab. One of them developed full blown hepatitis with seroreversion from anti-HBs to HBsAg after four weeks of alemtuzumab therapy. Lamivudine (100 mg die) achieved a complete clinical recovery and HBV-DNA clearancefrom blood within 8 weeks. The second patient (HBsAg and HBV-DNA seronegative, anti-HBs and anti-HBc positive before treatment) was kept under prophylaxis with lamivudine up to three months afteralemtuzumab. Two months after withdrawal of lamivudine, clinical and laboratory features of acute hepatitis B developed. Lamivudine therapy was restarted and a prompt recovery was obtained with HBsAg and HBV-DNA clearance.
Lingua originaleEnglish
pagine (da-a)254-258
Numero di pagine5
RivistaEuropean Journal of Haematology
Volume74
Stato di pubblicazionePublished - 2005

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Entra nei temi di ricerca di 'Hepatitis B virus reactivation andalemtuzumab therapy'. Insieme formano una fingerprint unica.

  • Cita questo